



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/623,065	07/18/2003	Subhashis Banerjee	BBC-202	3533
7590	09/12/2006		EXAMINER	
Tara Seshadri Abbott Boirearch Center 100 Research Drive Worcester, MA 01605			BLANCHARD, DAVID J	
			ART UNIT	PAPER NUMBER
			1643	

DATE MAILED: 09/12/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

XAV

<b>Office Action Summary</b>	Application No.	Applicant(s)	
	10/623,065	BANERJEE ET AL.	
	Examiner	Art Unit	
	David J. Blanchard	1643	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 19 June 2006.  
 2a) This action is FINAL.                    2b) This action is non-final.  
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 1-25 is/are pending in the application.  
 4a) Of the above claim(s) 6,14,20,24 and 25 is/are withdrawn from consideration.  
 5) Claim(s) \_\_\_\_\_ is/are allowed.  
 6) Claim(s) 1-5,7-13,15-19 and 21-23 is/are rejected.  
 7) Claim(s) \_\_\_\_\_ is/are objected to.  
 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.  
 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
 a) All    b) Some \* c) None of:  
 1. Certified copies of the priority documents have been received.  
 2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- 1) Notice of References Cited (PTO-892)  
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  
 3) Information Disclosure Statement(s) (PTO/SB/08)  
 Paper No(s)/Mail Date 9/30/2005.
- 4) Interview Summary (PTO-413)  
 Paper No(s)/Mail Date. \_\_\_\_\_.  
 5) Notice of Informal Patent Application  
 6) Other: \_\_\_\_\_.

**DETAILED ACTION**

1. The preliminary amendment filed 14 April 2004 has been entered in full.

***Election/Restrictions***

2. Applicant's election with traverse of the invention of Group I, claims 1-24 and species (a), restenosis, in the reply filed on 19 June 2006 is acknowledged. The traversal is on the grounds that the claims of Groups I and II are not independent and distinct, are drawn to a single inventive concept and a single inventive effort and the search and examination of both groups would not place a serious burden on the examiner. Applicants' remarks have been fully considered but are not found persuasive. MPEP 803 states that restriction is proper between patentably distinct inventions where the inventions are (1) independent or distinct as claimed and (2) a serious search burden is placed on the examiner if restriction is not required. While related, the inventions of Groups I and II are distinct in that the antibody of Group II can be used for affinity purification and/or detection assays in addition to the materially different therapeutic method of Group I, which differs in the method objectives, method steps, parameters, reagents used and different endpoints and are separately patentable (see MPEP 806.05(h)). Clearly, different searches and patentability issues are involved in the examination of each Group.

In regard to burden of search and examination, MPEP 803 states that a burden can be shown if the examiner shows either separate classification, different field of search or separate status in the art. In the instant case a burden

has been established in showing that the therapeutic method of Group I is classified in class 424, subclass 145.1, whereas the kit comprising the antibody of Group II is classified in class 530, subclass 388.23. The divergent classification of subject matter is merely one indication of the burdensome nature of the search involved. The literature search, particularly relevant in this art, is not co-extensive and is much more important in evaluating the burden of search. Clearly different searches and different patentability issues are involved in the examination of each group. For these reasons the restriction requirement is deemed to be proper and is made FINAL.

3. Claims 6, 14, 20 and 25-26 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention. It is noted that applicant did not provide a listing of all claims readable upon applicants elected species (i.e., restenosis) as required in the election/restriction requirement. In the interest of compact prosecution, claims 6, 14 and 20 have been withdrawn as not readable upon applicants' elected species.

4. It is noted that claim 22 is missing. To preserve the consecutive numbering of the claims in accordance with 37 C.F.R. 1.126, the examiner has renumbered claims 23-26 as claims 22-25, respectively. Applicants' reply to the instant Office Action should incorporate the renumbering of the claims and any newly added claims should begin with claim 26.

5. Claims 1-5, 7-13, 15-19 and 21-23 are under examination to the extent that the coronary disorder is restenosis, i.e., the elected species.

***Specification***

6. The disclosure is objected to because of the following informalities:
  - a. The specification discloses various non-provisional US Application numbers that should be updated with their current status, i.e., "now abandoned" or "U.S. Patent Number ....", or updated during the pendency of the present application should their status change. For example, see pg. 1, lines 12-28, pg. 8, lines 3 and 18 and pg. 9, line 14. Applicants' cooperation is requested in reviewing the entire disclosure for additional non-provisional U.S. Application Numbers that require updating.
  - b. The use of various trademarks have been noted in this application. For example, see pp. 4, 7, 16, 28, 45 as well as others. It should be capitalized wherever it appears and be accompanied by the generic terminology. Applicants' cooperation is requested in reviewing the entire disclosure for additional trademarks that require correction.

Although the use of trademarks is permissible in patent applications, the proprietary nature of the marks should be respected and every effort made to prevent their use in any manner, which might adversely affect their validity as trademarks.
  - c. The title of the invention is not descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed. Applicant should restrict the title to the treatment of restenosis using human TNF $\alpha$  antibodies.

Appropriate correction is required.

***Claim Objections***

7. Claims 1-4, 12, 15 and 18 are objected to as being drawn to non-elected inventions and as depending from a withdrawn claim (e.g., claim 15).  
Appropriate correction is required.
8. Claims 4 and 10 are objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claims, or amend the claims to place the claims in proper dependent form, or rewrite the claims in independent form. As depending from base claims 2 and 8, respectively, claims 4 and 10 recite that the antibody is D2E7, which does not incorporate the CDR3 amino acid substitutions of base claims 2 and 8 and thus, do not further limit the subject matter of previous claims 2 and 8. Applicant is reminded that a claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers and requires the dependent claim to further limit the subject matter claimed.

***Claim Rejections - 35 USC § 112***

9. The following is a quotation of the first paragraph of 35 U.S.C. 112:  

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
10. Claims 4, 10, 15, 17-19 and 21-23 are rejected under 35 U.S.C. § 112, first paragraph, because the specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the

invention, because the specification does not provide evidence that the claimed biological materials are (1) known and readily available to the public; (2) reproducible from the written description.

It is unclear if a cell line, which produces an antibody having the exact chemical identity of antibody D2E7 is known and publicly available, or can be reproducibly isolated without undue experimentation. Therefore, a suitable deposit for patent purposes is suggested. Without a publicly available deposit of the above cell line, one of ordinary skill in the art could not be assured of the ability to practice the invention as claimed. Exact replication of: (1) the claimed cell line; (2) a cell line which produces the chemically and functionally distinct antibody claimed; and/or (3) the claimed antibody's amino acid or nucleic acid sequence is an unpredictable event.

For example, very different  $V_H$  chains (about 50% homologous) can combine with the same  $V_K$  chain to produce antibody-binding sites with nearly the same size, shape, antigen specificity, and affinity. A similar phenomenon can also occur when different  $V_H$  sequences combine with different  $V_K$  sequences to produce antibodies with very similar properties. The results indicate that divergent variable region sequences, both in and out of the complementarity-determining regions, can be folded to form similar binding site contours, which result in similar immunochemical characteristics. Fundamental Immunology, William E. Paul, M.D. ed., 3rd ed., pg. 242, 1993. Therefore, it would require undue experimentation to reproduce the claimed antibody species antibody D2E7.

The specification lacks complete deposit information for the deposit of anti-TNF $\alpha$  antibody D2E7. It is unclear whether antibodies possessing the identical properties of antibody D2E7 are known and publicly available or can be reproducibly isolated from nature without undue experimentation.

Because one of ordinary skill in the art could not be assured of the ability to practice the invention as claimed in the absence of the availability of the claimed antibody D2E7, a suitable deposit is required for patent purposes, evidence of public availability of the claimed antibody or evidence of the reproducibility without undue experimentation of the claimed antibody, is required.

If the deposit is made under the provisions of the Budapest Treaty, filing of an affidavit or declaration by applicant or assignees or a statement by an attorney of record who has authority and control over the conditions of deposit over his or her signature and registration number stating that the deposit of antibody D2E7 has been accepted by an International Depository Authority under the provisions of the Budapest Treaty and that all restrictions upon public access to the deposited material will be irrevocably removed upon the grant of a patent on this application. This requirement is necessary when deposits are made under the provisions of the Budapest Treaty as the Treaty leaves this specific matter to the discretion of each State.

If the deposit of antibody D2E7 is not made under the provisions of the Budapest Treaty, then in order to certify that the deposit complies with the criteria set forth in 37 CFR 1.801-1.809 regarding availability and permanency of

deposits, assurance of compliance is required. Such assurance may be in the form of an affidavit or declaration by applicants or assignees or in the form of a statement by an attorney of record who has the authority and control over the conditions of deposit over his or her signature and registration number averring:

- (a) during the pendency of this application, access to the deposits will be afforded to the Commissioner upon request;
- (b) all restrictions upon the availability to the public of the deposited biological material will be irrevocably removed upon the granting of a patent on this application;
- (c) the deposits will be maintained in a public depository for a period of at least thirty years from the date of deposit or for the enforceable life of the patent or for a period of five years after the date of the most recent request for the furnishing of a sample of the deposited biological material, whichever is longest; and
- (d) the deposits will be replaced if they should become nonviable or non-replicable.

Amendment of the specification to recite the date of deposit and the complete name and address of the depository is required. As an additional means for completing the record, applicant may submit a copy of the contract with the depository for deposit and maintenance of each deposit.

If a deposit is made after the effective filing date of the application for patent in the United States, a verified statement is required from a person in a position to corroborate that the biological material described in the specification as filed is the same as that deposited in the depository, stating that the deposited material is identical to the biological material described in the specification and was in the applicant's possession at the time the application was filed. See MPEP 2406 and 37 CFR 1.804(b).

Applicant's attention is directed to In re Lundak, 773 F.2d. 1216, 227 USPQ 90 (CAFC 1985) and 37 CFR 1.801-1.809 for further information concerning deposit practice.

11. Claims 1-5, 7-11, 18-19 and 21-23 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a method of treating restenosis in a subject comprising administering a human anti-human TNF $\alpha$  antibody or antigen-binding fragment thereof comprising a light chain comprising CDR1 of SEQ ID NO:7, CDR2 of SEQ ID NO:5 and CDR3 of SEQ ID NO:3 comprising the recited amino acid substitutions and a heavy chain comprising CDR1 of SEQ ID NO:8, CDR2 of SEQ ID NO:6 and CDR3 of SEQ ID NO:4 comprising the recited amino acid substitutions, does not reasonably provide enablement for (i) a method of treating restenosis in a subject comprising administering a human anti-human TNF $\alpha$  antibody or antigen-binding fragment thereof comprising a light chain comprising CDR3 of SEQ ID NO:3 comprising the recited amino acid substitutions and a heavy chain comprising a heavy chain comprising CDR3 of SEQ ID NO:4 comprising the recited amino acid substitutions (i.e., claims 2, 5, 8 and 11) or (ii) a method of preventing restenosis in a subject or treating a subject at risk of developing restenosis, which broadly embraces prevention, comprising administering a human anti-human TNF $\alpha$  antibody or antigen-binding fragment thereof as broadly encompassed by the claims. The specification does not enable any person skilled in the art to which it

pertains, or with which it is most nearly connected, to make or use the invention commensurate in scope with these claims.

Factors to be considered in determining whether a disclosure meets the enablement requirement of 35 USC 112, first paragraph, have been described by the court in *In re Wands*, 8 USPQ2d 1400 (CA FC 1988).

Wands states on page 1404, "Factors to be considered in determining whether a disclosure would require undue experimentation have been summarized by the board in *Ex parte Forman*. They include (1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims."

The nature of the invention is engineered antibodies and immunotherapy where the relative level of skill of those in the art is deemed to be high.

The claims are broadly drawn to a method of treating or preventing restenosis in a subject comprising administering a human anti-human TNF $\alpha$  antibody or antigen-binding fragment thereof that dissociates from human TNF $\alpha$  with a K<sub>off</sub> of 1 x 10<sup>-3</sup> s<sup>-1</sup> or less, as determined by surface plasmon resonance; (b) has a light chain CDR3 domain comprising the amino acid sequence of SEQ ID NO:3, or modified from SEQ ID NO:3 by a single alanine substitution at position 1, 4, 5, 7 or 8 or by one to five conservative amino acid substitutions at positions 1, 3, 4, 6, 7, 8 and/or 9; (c) has a heavy chain CDR3 domain comprising the amino acid sequence of SEQ ID NO:4, or modified from SEQ ID NO: 4 by a single alanine substitution at position 2, 3, 4, 5, 6, 8, 9, 10 or 11 or by one to five conservative amino acid substitutions at positions 2, 3, 4, 5, 6, 8, 9,

10, 11 and/or 12. Thus, the claims encompass anti-human TNF $\alpha$  antibodies that comprise mutant CDR3 regions of antibody D2E7 and do not comprise the heavy and light chain CDR1 and CDR2 regions from antibody D2E7 for the clinical treatment of restenosis and the prevention of restenosis in a subject comprising administering a neutralizing, high affinity human anti-human TNF $\alpha$  antibody or antigen-binding fragment thereof.

The specification discloses only human anti-human TNF $\alpha$  antibodies and antigen-binding fragments thereof that comprise all six CDRs, three from the heavy chain and three from the light chain of human anti-human TNF $\alpha$  antibody D2E7 for the treatment of restenosis (see examples). The specification does not teach human anti-human TNF $\alpha$  antibodies or antigen-binding fragments thereof that only comprise the mutant CDR3 regions of the heavy and light chains of antibody D2E7, which do not contain the CDR1 and CDR2 regions of antibody D2E7 and do not bind human TNF $\alpha$ . The specification does not teach the prevention of restenosis in a subject comprising administering the presently claimed human anti-TNF $\alpha$  antibodies. There are no working examples of human anti-human TNF $\alpha$  antibodies or antigen-binding fragments thereof that only comprise the mutant CDR3 regions of the heavy and light chains of antibody D2E7, wherein the antibodies or antigen-binding fragments thereof bind human TNF $\alpha$  and dissociates from human TNF $\alpha$  with a K<sub>off</sub> of 1 x 10<sup>-3</sup> s<sup>-1</sup> or less. There are no working examples that restenosis can be prevented in a subject comprising administering the claimed human anti-TNF $\alpha$  antibodies. The scope

of the claims must bear a reasonable correlation with the scope of enablement.

See In re Fisher, 166 USPQ 19 24 (CCPA 1970).

The state of the prior art is such that it is well established in the art that the formation of an intact antigen-binding site of antibodies requires the association of the complete heavy and light chain variable regions of a given antibody, each of which consists of three CDRs or hypervariable regions, which provide the majority of the contact residues for the binding of the antibody to its target epitope (Paul, Fundamental Immunology, 3<sup>rd</sup> Edition, 1993, pp. 292-295, under the heading "Fv Structure and Diversity in Three Dimensions"). The amino acid sequences and conformations of each of the heavy and light chain CDRs are critical in maintaining the antigen binding specificity and affinity, which is characteristic of the immunoglobulin. It is expected that all of the heavy and light chain CDRs in their proper order and in the context of framework sequences which maintain their required conformation, are required in order to produce a protein having antigen-binding function and that proper association of heavy and light chain variable regions is required in order to form functional antigen binding sites (Paul, page 293, first column, lines 3-8 and line 31 to column 2, line 9 and lines 27-30). Even minor changes in the amino acid sequences of the heavy and light variable regions, particularly in the CDRs, may dramatically affect antigen-binding function as evidenced by Rudikoff et al (Proc. Natl. Acad. Sci. USA, 79(6):1979-1983, March 1982). Rudikoff et al. teach that the alteration of a single amino acid in the CDR of a phosphocholine-binding myeloma protein resulted in the loss of antigen-binding function. It is unlikely that human anti-

human TNF $\alpha$  antibodies and antigen-binding fragments thereof, which do not contain all of the heavy and light chain CDRs of antibody D2E7 in their proper order and in the context of framework sequences which maintain their correct spatial orientation have the requisite human TNF $\alpha$ -binding function. There is insufficient guidance and direction to assist those skilled in the art in producing human anti-human TNF $\alpha$  antibodies that only comprise mutant CDR3 regions of antibody D2E7 that bind human TNF $\alpha$ . Applicants have provided insufficient evidence or nexus that would lead the skilled artisan to predict the ability of producing human anti-human TNF $\alpha$  antibodies, which contain less than the full complement of CDRs of antibody D2E7 and comprising the recited heavy and light chain CDR3 amino acid substitutions, wherein the antibody binds human TNF $\alpha$  and dissociates from human TNF $\alpha$  with a K<sub>off</sub> of 1 x 10<sup>-3</sup> s<sup>-1</sup> or less and effectively treats restenosis in a subject. Further, there is insufficient evidence or nexus between the administration of the claimed human anti-TNF $\alpha$  antibodies in a subject and the prevention of restenosis. One of skill in the art would neither expect nor predict the appropriate functioning of the human anti-human TNF $\alpha$  antibodies as broadly as is claimed.

In view of the lack of the predictability of the art to which the invention pertains as evidenced by Paul W. E. and Rudikoff et al, the lack of guidance and direction provided by applicant, and the absence of working examples, undue experimentation would be required to practice the claimed therapeutic method comprising human anti-human TNF $\alpha$  antibodies, which contain less than the full

complement of CDRs of antibody D2E7 with a reasonable expectation of success, absent a specific and detailed description in applicant's specification of how to effectively practice the claimed human anti-human TNF $\alpha$  antibodies and absent working examples providing evidence which is reasonably predictive that the claimed human anti-human TNF $\alpha$  antibodies bind human TNF $\alpha$  and dissociates from human TNF $\alpha$  with a  $K_{off}$  of  $1 \times 10^{-3} \text{ s}^{-1}$  or less, commensurate in scope with the claimed invention.

### ***Claim Rejections - 35 USC § 103***

12. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that

the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary.

Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

13. Claims 1-5, 7-13, 15-19 and 21-23 are rejected under 35 U.S.C. 103(a) as being unpatentable over Clausell et al (British Heart Journal, 73(6):534-539, June 1995, IDS reference filed 9/30/2005) in view of Salfeld et al [a] (WO 97/29131, publication date 8/14/1997, IDS reference filed 9/30/2005) and Poon et al (Lancet, 359(9306):619-622, February 2002).

The claims are being interpreted as drawn to a method of treating restenosis in a subject comprising administering a therapeutically effective amount of a neutralizing, high affinity TNF $\alpha$  antibody or antigen-binding fragment thereof such that type 2 diabetes mellitus is treated, wherein the antibody is an isolated human antibody or antigen-binding fragment thereof that dissociates from human TNF $\alpha$  with a  $K_d$  of  $1 \times 10^{-8}$  M or less and a  $K_{off}$  of  $1 \times 10^{-3}$  s $^{-1}$  or less, as determined by surface plasmon resonance, and neutralizes human TNF $\alpha$  cytotoxicity in a standard *in vitro* L929 assay with an IC $_{50}$  of  $1 \times 10^{-7}$  M or less, and wherein the isolated human antibody or antigen-binding fragment thereof antibody has the following characteristics: (a) dissociates from human TNF $\alpha$  with a  $K_{off}$  of  $1 \times 10^{-3}$  s $^{-1}$  or less, as determined by surface plasmon resonance; (b) has

a light chain CDR3 domain comprising the amino acid sequence of SEQ ID NO:3, or modified from SEQ ID NO:3 by a single alanine substitution at position 1, 4, 5, 7 or 8 or by one to five conservative amino acid substitutions at positions 1, 3, 4, 6, 7, 8 and/or 9; (c) has a heavy chain CDR3 domain comprising the amino acid sequence of SEQ ID NO:4, or modified from SEQ ID NO: 4 by a single alanine substitution at position 2, 3, 4, 5, 6, 8, 9, 10 or 11 or by one to five conservative amino acid substitutions at positions 2, 3, 4, 5, 6, 8, 9, 10, 11 and/or 12, or wherein the isolated human antibody or antigen-binding fragment thereof comprises a light chain variable region comprising SEQ ID NO:1 and a heavy chain variable region comprising SEQ ID NO:2, or the antibody is D2E7, or the antibody is administered with at least one additional therapeutic agent selected from sirolimus, paclitaxol, everolimus, racolimus, ABT-578 and acetaminophen.

Clausell et al teach that restenosis is associated with increased expression of TNF $\alpha$  and fibronectin and neutralization of TNF $\alpha$  activity after cardiac transplantation reduced the severity and number of coronary artery lesions and this was associated with less inflammation and reduced accumulation of fibronectin in the vessel wall (see entire document, particularly pp. 536-538 and abstract). Clausell et al do not specifically teach the presently claimed human antibody or antigen-binding fragment thereof that dissociates from human TNF $\alpha$  with a  $K_d$  of  $1 \times 10^{-8}$  M or less and a  $K_{off}$  of  $1 \times 10^{-3} s^{-1}$  or less, as determined by surface plasmon resonance, and neutralizes human TNF $\alpha$  cytotoxicity in a standard *in vitro* L929 assay with an IC<sub>50</sub> of  $1 \times 10^{-7}$  M or less, and wherein the isolated human antibody or antigen-binding fragment thereof

antibody has the following characteristics: (a) dissociates from human TNF $\alpha$  with a  $K_{off}$  of  $1 \times 10^{-3} \text{ s}^{-1}$  or less, as determined by surface plasmon resonance; (b) has a light chain CDR3 domain comprising the amino acid sequence of SEQ ID NO:3, or modified from SEQ ID NO:3 by a single alanine substitution at position 1, 4, 5, 7 or 8 or by one to five conservative amino acid substitutions at positions 1, 3, 4, 6, 7, 8 and/or 9; (c) has a heavy chain CDR3 domain comprising the amino acid sequence of SEQ ID NO:4, or modified from SEQ ID NO: 4 by a single alanine substitution at position 2, 3, 4, 5, 6, 8, 9, 10 or 11 or by one to five conservative amino acid substitutions at positions 2, 3, 4, 5, 6, 8, 9, 10, 11 and/or 12, or wherein the isolated human antibody or antigen-binding fragment thereof comprises a light chain variable region comprising SEQ ID NO:1 and a heavy chain variable region comprising SEQ ID NO:2, or the antibody is D2E7, or the antibody is administered with at least one additional therapeutic agent selected from sirolimus, paclitaxol, everolimus, racolimus, ABT-578 and acetaminophen. These deficiencies are made up for in the teachings of Salfeld et al [a] and Poon et al.

Salfeld et al [a] teach a method for treating TNF $\alpha$ -related disorders, including coronary disorders in a subject comprising administering a therapeutically effective amount of a neutralizing, high affinity human anti-human TNF $\alpha$  antibody or antigen-binding fragment thereof identical to the claimed human anti-human TNF $\alpha$  antibodies, i.e., dissociates from human TNF $\alpha$  with a  $K_d$  of  $1 \times 10^{-8} \text{ M}$  or less and has a  $K_{off}$  of  $1 \times 10^{-3} \text{ s}^{-1}$  or less, as determined by surface plasmon resonance, and neutralizes human TNF $\alpha$  cytotoxicity in a

standard *in vitro* L929 assay with an IC<sub>50</sub> of 1 × 10<sup>-7</sup> M or less, and the human antibody or antigen-binding fragment thereof antibody has the following characteristics: (a) dissociates from human TNF $\alpha$  with a K<sub>off</sub> of 1 × 10<sup>-3</sup> s<sup>-1</sup> or less, as determined by surface plasmon resonance; (b) has a light chain CDR3 domain comprising the amino acid sequence of SEQ ID NO:3, or modified from SEQ ID NO:3 by a single alanine substitution at position 1, 4, 5, 7 or 8 or by one to five conservative amino acid substitutions at positions 1, 3, 4, 6, 7, 8 and/or 9; (c) has a heavy chain CDR3 domain comprising the amino acid sequence of SEQ ID NO:4, or modified from SEQ ID NO: 4 by a single alanine substitution at position 2, 3, 4, 5, 6, 8, 9, 10 or 11 or by one to five conservative amino acid substitutions at positions 2, 3, 4, 5, 6, 8, 9, 10, 11 and/or 12, and wherein the human antibody or antigen-binding fragment thereof comprises a light chain variable region comprising SEQ ID NO:1 and a heavy chain variable region comprising SEQ ID NO:2, and the antibody is D2E7, and the antibody is administered with at least one or more additional therapeutic agents (see entire document, particularly pp. 3-6, 12-17, 29-31, 35-36 and 39).

Poon et al teach treating restenosis with sirolimus.

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the claimed invention was made to use the neutralizing, high affinity human anti-human TNF $\alpha$  antibodies or an antigen-binding fragment thereof of Salfeld et al [a], and administered with at least one additional therapeutic agent, including sirolimus as taught by Poon et al for the treatment of restenosis in a human patient.

One of ordinary skill in the art would have been motivated to and had a reasonable expectation of success at the time the invention was made to use the neutralizing, high affinity human anti-human TNF $\alpha$  antibodies or an antigen-binding fragment thereof of Salfeld et al [a], and administered with at least one additional therapeutic agent, including sirolimus as taught by Poon et al for the treatment of restenosis in a human patient because Clausell et al teach that restenosis is associated with increased expression of TNF $\alpha$  and fibronectin and neutralization of TNF $\alpha$  activity after cardiac transplantation reduced the severity and number of coronary artery lesions and Salfeld et al [a] teach neutralizing, high affinity human anti-human TNF $\alpha$  antibody and antigen-binding fragments thereof for treating TNF $\alpha$ -related disorders, including coronary disorders in a human subject comprising administering a therapeutically effective amount of a human anti-human TNF $\alpha$  antibody or antigen-binding fragment thereof identical to the claimed human anti-human TNF $\alpha$  antibodies, i.e., identical structures/sequences, binding kinetics and neutralization properties (discussed supra) and administered with one or more additional therapeutic agents and Poon et al teach sirolimus administration for overcoming restenosis. Therefore, one of ordinary skill in the art at the time the invention was made would have been motivated to use the human anti-human TNF $\alpha$  antibodies and antigen-binding fragments thereof of Salfeld et al [a] for improving restenotic lesions in human patients since TNF $\alpha$  neutralization after cardiac transplantation reduced the severity and number of coronary artery lesions and the human anti-human

TNF $\alpha$  antibodies and antigen-binding fragments thereof of Salfeld et al [a] are entirely human anti-human TNF $\alpha$  antibodies and should not elicit an immunogenic response according to Salfeld et al [a] (e.g., pg. 2, lines 8-17). Thus, it would have been *prima facie* obvious to one skilled in the art at the time the invention was made to use the neutralizing, high affinity human anti-human TNF $\alpha$  antibodies or an antigen-binding fragment thereof of Salfeld et al [a], and administered with at least one additional therapeutic agent, including sirolimus as taught for the treatment of restenosis in a human patient in view of Clausell et al and Salfeld et al [a] and Poon et al.

Therefore, the invention as a whole was *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references.

14. Claims 1-5, 7-13, 15-19 and 21-23 are rejected under 35 U.S.C. 103(a) as being unpatentable over Clausell et al (British Heart Journal, 73(6):534-539, June 1995, IDS reference filed 9/30/2005) in view of Salfeld et al [b] (US Patent 6,509,015 B1, 2/9/1996, IDS reference filed 9/30/2005) and Poon et al (Lancet, 359(9306):619-622, February 2002).

The applied reference has a common inventor with the instant application. Based upon the earlier effective U.S. filing date of the reference, it constitutes prior art under 35 U.S.C. 102(e). This rejection under 35 U.S.C. 102(e) might be overcome either by a showing under 37 CFR 1.132 that any invention disclosed but not claimed in the reference was derived from the inventor of this application

and is thus not the invention "by another," or by an appropriate showing under 37 CFR 1.131.

The claims and their interpretation have been described supra.

Clausell et al have been described supra. Clausell et al do not specifically teach the presently claimed human antibody or antigen-binding fragment thereof that dissociates from human TNF $\alpha$  with a  $K_d$  of  $1 \times 10^{-8}$  M or less and a  $K_{off}$  of  $1 \times 10^{-3} s^{-1}$  or less, as determined by surface plasmon resonance, and neutralizes human TNF $\alpha$  cytotoxicity in a standard *in vitro* L929 assay with an  $IC_{50}$  of  $1 \times 10^{-7}$  M or less, and wherein the isolated human antibody or antigen-binding fragment thereof antibody has the following characteristics: (a) dissociates from human TNF $\alpha$  with a  $K_{off}$  of  $1 \times 10^{-3} s^{-1}$  or less, as determined by surface plasmon resonance; (b) has a light chain CDR3 domain comprising the amino acid sequence of SEQ ID NO:3, or modified from SEQ ID NO:3 by a single alanine substitution at position 1, 4, 5, 7 or 8 or by one to five conservative amino acid substitutions at positions 1, 3, 4, 6, 7, 8 and/or 9; (c) has a heavy chain CDR3 domain comprising the amino acid sequence of SEQ ID NO:4, or modified from SEQ ID NO: 4 by a single alanine substitution at position 2, 3, 4, 5, 6, 8, 9, 10 or 11 or by one to five conservative amino acid substitutions at positions 2, 3, 4, 5, 6, 8, 9, 10, 11 and/or 12, or wherein the isolated human antibody or antigen-binding fragment thereof comprises a light chain variable region comprising SEQ ID NO:1 and a heavy chain variable region comprising SEQ ID NO:2, or the antibody is D2E7, or the antibody is administered with at least one additional therapeutic agent selected from sirolimus, paclitaxol, everolimus, racolimus,

ABT-578 and acetaminophen. These deficiencies are made up for in the teachings of Salfeld et al [b] and Poon et al.

Salfeld et al [b] teach a method for treating TNF $\alpha$ -related disorders, including coronary disorders in a subject comprising administering a therapeutically effective amount of a neutralizing, high affinity human anti-human TNF $\alpha$  antibody or antigen-binding fragment thereof identical to the claimed human anti-human TNF $\alpha$  antibodies, i.e., dissociates from human TNF $\alpha$  with a  $K_d$  of  $1 \times 10^{-8}$  M or less and has a  $K_{off}$  of  $1 \times 10^{-3}$  s $^{-1}$  or less, as determined by surface plasmon resonance, and neutralizes human TNF $\alpha$  cytotoxicity in a standard *in vitro* L929 assay with an IC<sub>50</sub> of  $1 \times 10^{-7}$  M or less, and the human antibody or antigen-binding fragment thereof antibody has the following characteristics: (a) dissociates from human TNF $\alpha$  with a  $K_{off}$  of  $1 \times 10^{-3}$  s $^{-1}$  or less, as determined by surface plasmon resonance; (b) has a light chain CDR3 domain comprising the amino acid sequence of SEQ ID NO:3, or modified from SEQ ID NO:3 by a single alanine substitution at position 1, 4, 5, 7 or 8 or by one to five conservative amino acid substitutions at positions 1, 3, 4, 6, 7, 8 and/or 9; (c) has a heavy chain CDR3 domain comprising the amino acid sequence of SEQ ID NO:4, or modified from SEQ ID NO: 4 by a single alanine substitution at position 2, 3, 4, 5, 6, 8, 9, 10 or 11 or by one to five conservative amino acid substitutions at positions 2, 3, 4, 5, 6, 8, 9, 10, 11 and/or 12, or wherein the human antibody or antigen-binding fragment thereof comprises a light chain variable region comprising SEQ ID NO:1 and a heavy chain variable region comprising SEQ ID NO:2, or the antibody is D2E7, or the antibody is

administered with at least one or more additional therapeutic agents (see entire document, particularly columns 2-4, 9-13, 22-24 and 27).

Poon et al have been described supra.

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the claimed invention was made to use the neutralizing, high affinity human anti-human TNF $\alpha$  antibodies or an antigen-binding fragment thereof of Salfeld et al [b], and administered with at least one additional therapeutic agent, including sirolimus as taught by Poon et al for the treatment of restenosis in a human patient.

One of ordinary skill in the art would have been motivated to and had a reasonable expectation of success at the time the invention was made to use the neutralizing, high affinity human anti-human TNF $\alpha$  antibodies or an antigen-binding fragment thereof of Salfeld et al [b], and administered with at least one additional therapeutic agent, including sirolimus as taught by Poon et al for the treatment of restenosis in a human patient because Clausell et al teach that restenosis is associated with increased expression of TNF $\alpha$  and fibronectin and neutralization of TNF $\alpha$  activity after cardiac transplantation reduced the severity and number of coronary artery lesions and Salfeld et al [b] teach neutralizing, high affinity human anti-human TNF $\alpha$  antibody and antigen-binding fragments thereof for treating TNF $\alpha$ -related disorders, including coronary disorders in a human subject comprising administering a therapeutically effective amount of a human anti-human TNF $\alpha$  antibody or antigen-binding fragment thereof identical

to the claimed human anti-human TNF $\alpha$  antibodies, i.e., identical structures/sequences, binding kinetics and neutralization properties (discussed supra) and administered with one or more additional therapeutic agents and Poon et al teach sirolimus administration for overcoming restenosis. Therefore, one of ordinary skill in the art at the time the invention was made would have been motivated to use the human anti-human TNF $\alpha$  antibodies and antigen-binding fragments thereof of Salfeld et al [b] for improving restenotic lesions in human patients since TNF $\alpha$  neutralization after cardiac transplantation reduced the severity and number of coronary artery lesions and the human anti-human TNF $\alpha$  antibodies and antigen-binding fragments thereof of Salfeld et al [b] are entirely human anti-human TNF $\alpha$  antibodies and should not elicit an immunogenic response according to Salfeld et al [b] (e.g., col. 2, lines 1-13). Thus, it would have been *prima facie* obvious to one skilled in the art at the time the invention was made to use the neutralizing, high affinity human anti-human TNF $\alpha$  antibodies or an antigen-binding fragment thereof of Salfeld et al [b], and administered with at least one additional therapeutic agent, including sirolimus as taught for the treatment of restenosis in a human patient in view of Clausell et al and Salfeld et al [b] and Poon et al.

Therefore, the invention as a whole was *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references.

***Double Patenting***

15. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

16. Claims 1-5, 7-13, 15-19 and 21-23 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-7, 14, 36-39, 46 and 69-70 of U.S. Patent No. 6,509,015 B1 in view of Clausell et al (British Heart Journal, 73(6):534-539, June 1995, IDS reference filed 9/30/2005) and Poon et al (Lancet, 359(9306):619-622, February 2002). Although the conflicting claims are not identical, they are not patentably distinct from each other.

The instant claims and their interpretation have been described supra.

Claims 1-7, 14, 36-39, 46 and 69-70 of U.S. Patent No. 6,509,015 B1 are drawn to a method of inhibiting human TNF $\alpha$  activity in a human subject and a

method of treating a human subject suffering from a disorder in which TNF $\alpha$  activity is detrimental, including a cardiac disorder comprising administering to the human subject a human anti-human TNF $\alpha$  antibody or antigen-binding fragment thereof that is identical to the neutralizing, high affinity human anti-human TNF $\alpha$  antibodies and antigen-binding fragments thereof of the present claims, i.e., identical structures/sequences, binding kinetics and neutralization properties and wherein the administered human anti-human TNF $\alpha$  antibody or antigen binding fragment thereof is optionally administered with at least one additional therapeutic agent. Claims 1-7, 14, 36-39, 46 and 69-70 of U.S. Patent No. 6,509,015 B1 do not teach the administration of the human anti-human TNF $\alpha$  antibody or antigen-binding fragment thereof for the treatment of restenosis or wherein the human anti-human TNF $\alpha$  antibody is administered with at least one additional therapeutic agent selected from sirolimus, paclitaxol, everolimus, racolimus, ABT-578 and acetaminophen. These deficiencies are made up for in the teachings of Clausell et al and Poon et al.

Clausell et al have been described supra.

Poon et al have been described supra.

The claims in the instant application are obvious variants of claims 1-7, 14, 36-39, 46 and 69-70 of U.S. Patent No. 6,509,015 B1 because it would have been *prima facie* obvious to one of ordinary skill in the art at the time the claimed invention was made to treat restenosis in a human patient comprising administering the human anti-human TNF $\alpha$  antibodies or an antigen-binding fragment thereof according to claims 1-7, 14, 36-39, 46 and 69-70 of U.S. Patent

No. 6,509,015 B1, optionally with at least one additional therapeutic agent, including sirolimus.

One of ordinary skill in the art would have been motivated to and had a reasonable expectation of success at the time the invention was made to treat restenosis in a human patient comprising administering the human anti-human TNF $\alpha$  antibodies or an antigen-binding fragment thereof according to claims 1-7, 14, 36-39, 46 and 69-70 of U.S. Patent No. 6,509,015 B1, optionally with at least one additional therapeutic agent, including sirolimus in view of Clausell et al and Poon et al because Clausell et al teach that restenosis is associated with increased expression of TNF $\alpha$  and fibronectin and neutralization of TNF $\alpha$  activity after cardiac transplantation reduced the severity and number of coronary artery lesions and Poon et al teach sirolimus administration for overcoming restenosis. Thus, it would have been *prima facie* obvious to one of ordinary skill in the art at the time the claimed invention was made to administer the human anti-human TNF $\alpha$  antibodies or an antigen-binding fragment thereof of claims 1-7, 14, 36-39, 46 and 69-70 of U.S. Patent No. 6,509,015 B1, optionally with at least one additional therapeutic agent, including sirolimus in view of claims 1-7, 14, 36-39, 46 and 69-70 of U.S. Patent No. 6,509,015 B1 and Clausell et al and Poon et al.

Claims 1-5, 7-13, 15-19 and 21-23 are directed to an invention not patentably distinct from claims 1-7, 14, 36-39, 46 and 69-70 of commonly assigned U.S. Patent No. 6,509,015 B1. Specifically, see above.

The U.S. Patent and Trademark Office normally will not institute an interference between applications or a patent and an application of common

Art Unit: 1643

ownership (see MPEP Chapter 2300). Commonly assigned U.S. Patent No. 6,509,015 B1, discussed above, would form the basis for a rejection of the noted claims under 35 U.S.C. 103(a) if the commonly assigned case qualifies as prior art under 35 U.S.C. 102(e), (f) or (g) and the conflicting inventions were not commonly owned at the time the invention in this application was made. In order for the examiner to resolve this issue, the assignee can, under 35 U.S.C. 103(c) and 37 CFR 1.78(c), either show that the conflicting inventions were commonly owned at the time the invention in this application was made, or name the prior inventor of the conflicting subject matter.

A showing that the inventions were commonly owned at the time the invention in this application was made will preclude a rejection under 35 U.S.C. 103(a) based upon the commonly assigned case as a reference under 35 U.S.C. 102(f) or (g), or 35 U.S.C. 102(e) for applications pending on or after December 10, 2004.

17. Claims 1-5, 7-13, 15-19 and 21-23 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-23, 69 and 73-84 of copending Application No. 10/163,657 in view of Clausell et al (British Heart Journal, 73(6):534-539, June 1995, IDS reference filed 9/30/2005) and Poon et al (Lancet, 359(9306):619-622, February 2002). Although the conflicting claims are not identical, they are not patentably distinct from each other.

The instant claims have been described supra.

Claims 1-23, 69 and 73-84 of copending Application No. 10/163,657 are drawn to methods for treating a TNF $\alpha$  disorder, including a cardiac disorder in a human subject comprising administering an anti-TNF $\alpha$  antibody or antigen-binding fragment thereof on a biweekly dosing regimen, wherein the antibody or antigen-binding fragment thereof is a human antibody identical to the human anti-human TNF $\alpha$  antibodies claimed in the instant application, i.e., having identical structures/sequences, binding kinetics and neutralization properties. Claims 1-23, 69 and 73-84 of copending Application No. 10/163,657 do not teach the administration of at least one additional therapeutic agent selected from sirolimus, paclitaxol, everolimus, racolimus, ABT-578 and acetaminophen and wherein the administration is for the treatment of restenosis. These deficiencies are made up for in the teachings of Clausell et al and Poon et al.

Clausell et al have been described supra.

Poon et al have been described supra.

The claims in the instant application are obvious variants of claims 1-23, 69 and 73-84 of copending Application No. 10/163,657 because it would have been *prima facie* obvious to one of ordinary skill in the art at the time the claimed invention was made to treat restenosis in a human patient comprising administering the human anti-human TNF $\alpha$  antibodies or an antigen-binding fragment thereof according to claims 1-23, 69 and 73-84 of copending Application No. 10/163,657, optionally with at least one additional therapeutic agent including sirolimus in view of Clausell et al and Poon et al.

One of ordinary skill in the art would have been motivated to and had a reasonable expectation of success at the time the invention was made to treat restenosis in a human patient comprising administering the human anti-human TNF $\alpha$  antibodies or an antigen-binding fragment thereof according to claims 1-23, 69 and 73-84 of copending Application No. 10/163,657, optionally with at least one additional therapeutic agent including sirolimus in view of Clausell et al and Poon et al because Clausell et al teach that restenosis is associated with increased expression of TNF $\alpha$  and fibronectin and neutralization of TNF $\alpha$  activity after cardiac transplantation reduced the severity and number of coronary artery lesions and Poon et al teach sirolimus administration for overcoming restenosis. Thus, it would have been *prima facie* obvious to one of ordinary skill in the art at the time the claimed invention was made to administer the neutralizing, high affinity human anti-human TNF $\alpha$  antibodies or an antigen-binding fragment thereof of claims 1-23, 69 and 73-84 of copending Application No. 10/163,657, optionally with at least one additional therapeutic agent, including sirolimus in view of claims 1-23, 69 and 73-84 of copending Application No. 10/163,657 and Clausell et al and Poon et al.

Claims 1-5, 7-13, 15-19 and 21-23 are directed to an invention not patentably distinct from claims 1-23, 69 and 73-84 of commonly assigned copending Application No. 10/163,657. Specifically, see above.

The U.S. Patent and Trademark Office normally will not institute an interference between applications or a patent and an application of common ownership (see MPEP Chapter 2300). Commonly assigned copending

Application No. 10/163,657, discussed above, would form the basis for a rejection of the noted claims under 35 U.S.C. 103(a) if the commonly assigned case qualifies as prior art under 35 U.S.C. 102(e), (f) or (g) and the conflicting inventions were not commonly owned at the time the invention in this application was made. In order for the examiner to resolve this issue, the assignee can, under 35 U.S.C. 103(c) and 37 CFR 1.78(c), either show that the conflicting inventions were commonly owned at the time the invention in this application was made, or name the prior inventor of the conflicting subject matter.

A showing that the inventions were commonly owned at the time the invention in this application was made will preclude a rejection under 35 U.S.C. 103(a) based upon the commonly assigned case as a reference under 35 U.S.C. 102(f) or (g), or 35 U.S.C. 102(e) for applications pending on or after December 10, 2004.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

18. Claims 1-5, 7-13, 15-19 and 21-23 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim 15 of copending Application No. 11/233,252 in view of Clausell et al (British Heart Journal, 73(6):534-539, June 1995, IDS reference filed 9/30/2005) and Salfeld et al [a] (WO 97/29131, publication date 8/14/1997, IDS reference filed 9/30/2005) and Poon et al (Lancet, 359(9306):619-622, February 2002).

Although the conflicting claims are not identical, they are not patentably distinct from each other.

The instant claims and their interpretation have been described supra.

Claim 15 of copending Application No. 11/233,252 is drawn to a method for treating a subject suffering from a disorders in which TNF $\alpha$  activity is detrimental comprising administering a pharmaceutical composition comprising an isolated human anti-human TNF $\alpha$  antibody or antigen-binding fragment thereof that dissociates from human TNF $\alpha$  with a  $K_d$  of  $1 \times 10^{-8}$  M or less and has a  $K_{off}$  of  $1 \times 10^{-3}$  s $^{-1}$  or less, as determined by surface plasmon resonance, and neutralizes human TNF $\alpha$  cytotoxicity in a standard *in vitro* L929 assay with an IC<sub>50</sub> of  $1 \times 10^{-7}$  M or less. Claim 15 of copending Application No. 11/233,252 does not specifically teach human anti-human TNF $\alpha$  antibodies or antigen-binding fragments thereof having a  $K_{off}$  of  $1 \times 10^{-3}$  s $^{-1}$  or less and the light and heavy chain CDR3 sequences (SEQ ID Nos:3-4) or variants thereof or comprising the light chain variable region of SEQ ID NO:1 and the heavy chain variable region of SEQ ID NO:2 or wherein the anti-human TNF $\alpha$  antibody is antibody D2E7 or is administered in combination with at least one additional therapeutic agent selected from sirolimus, paclitaxol, everolimus, racolimus, ABT-578 and acetaminophen and wherein the administration is for treating restenosis. These deficiencies are made up for in the teachings of Clausell et al and Salfeld et al [a] and Poon et al.

Clausell et al have been described supra.

Salfeld et al [a] have been described supra.

Poon et al have been described supra.

The claims in the instant application are obvious variants of claim 15 of copending Application No. 11/233,252 because it would have been *prima facie* obvious to one of ordinary skill in the art at the time the claimed invention was made to treat restenosis in a human subject comprising administering the human anti-human TNF $\alpha$  antibodies of Salfeld et al [a], optionally in combination with at least one additional therapeutic agent, including sirolimus.

One of ordinary skill in the art would have been motivated to and had a reasonable expectation of success at the time the invention was made to treat restenosis in a human subject comprising administering the human anti-human TNF $\alpha$  antibodies of Salfeld et al [a], optionally in combination with at least one additional therapeutic agent, including sirolimus in view of claim 15 of copending Application No. 11/233,252 and Clausell et al and Salfeld et al [a] and Poon et al because Clausell et al teach that restenosis is associated with increased expression of TNF $\alpha$  and fibronectin and neutralization of TNF $\alpha$  activity after cardiac transplantation reduced the severity and number of coronary artery lesions and Salfeld et al [a] teach neutralizing, high affinity human anti-human TNF $\alpha$  antibody and antigen-binding fragments thereof for treating TNF $\alpha$ -related disorders, including coronary disorders in a human subject comprising administering a therapeutically effective amount of a human anti-human TNF $\alpha$  antibody or antigen-binding fragment thereof identical to the claimed human anti-human TNF $\alpha$  antibodies, i.e., identical structures/sequences, binding kinetics and neutralization properties (discussed supra) and administered with one or more

additional therapeutic agents and Poon et al teach sirolimus administration for overcoming restenosis. Therefore, one of ordinary skill in the art at the time the invention was made would have been motivated to use the human anti-human TNF $\alpha$  antibodies and antigen-binding fragments thereof of Salfeld et al [a] for improving restenotic lesions in human patients since TNF $\alpha$  neutralization after cardiac transplantation reduced the severity and number of coronary artery lesions and the human anti-human TNF $\alpha$  antibodies and antigen-binding fragments thereof of Salfeld et al [a] are entirely human anti-human TNF $\alpha$  antibodies and should not elicit an immunogenic response according to Salfeld et al [a] (e.g., pg. 2, lines 8-17). Thus, it would have been *prima facie* obvious to one of ordinary skill in the art at the time the claimed invention was made to treat restenosis in a human subject comprising administering the human anti-human TNF $\alpha$  antibodies of Salfeld et al [a], optionally in combination with at least one additional therapeutic agent, including sirolimus in view of claim 15 of copending Application No. 11/233,252 and Clausell et al and Salfeld et al [a] and Poon et al.

Claims 1-5, 7-13, 15-19 and 21-23 are directed to an invention not patentably distinct from claim 15 of commonly assigned copending Application No. 11/233,252. Specifically, see above.

The U.S. Patent and Trademark Office normally will not institute an interference between applications or a patent and an application of common ownership (see MPEP Chapter 2300). Commonly assigned copending Application No. 11/233,252, discussed above, would form the basis for a

Art Unit: 1643

rejection of the noted claims under 35 U.S.C. 103(a) if the commonly assigned case qualifies as prior art under 35 U.S.C. 102(e), (f) or (g) and the conflicting inventions were not commonly owned at the time the invention in this application was made. In order for the examiner to resolve this issue, the assignee can, under 35 U.S.C. 103(c) and 37 CFR 1.78(c), either show that the conflicting inventions were commonly owned at the time the invention in this application was made, or name the prior inventor of the conflicting subject matter.

A showing that the inventions were commonly owned at the time the invention in this application was made will preclude a rejection under 35 U.S.C. 103(a) based upon the commonly assigned case as a reference under 35 U.S.C. 102(f) or (g), or 35 U.S.C. 102(e) for applications pending on or after December 10, 2004.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

19. Claims 1-5, 7-13, 15-19 and 21-23 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-5, 7, 9-18 and 21 of copending Application No. 11/104,117 in view of Clausell et al (British Heart Journal, 73(6):534-539, June 1995, IDS reference filed 9/30/2005) and Salfeld et al [a] (WO 97/29131, publication date 8/14/1997, IDS reference filed 9/30/2005) and Poon et al (Lancet, 359(9306):619-622, February 2002). Although the conflicting claims are not identical, they are not patentably distinct from each other.

The instant claims and their interpretation have been described supra.

Claims 1-5, 7, 9-18 and 21 of copending Application No. 11/104,117 are drawn to a multiple-variable dose method for treating a disorder in which TNF $\alpha$  activity is detrimental including a cardiac disorder comprising administering to a subject at least one induction dose of TNF $\alpha$  inhibitor such that a threshold level of TNF $\alpha$  inhibitor is achieved within an induction phase and subsequently administering to the subject at least one treatment dose of the TNF $\alpha$  inhibitor within a treatment phase, such that treatment occurs and wherein the TNF $\alpha$  inhibitor is a human anti-human TNF $\alpha$  antibody or antigen-binding fragment thereof that is identical to the human anti-human TNF $\alpha$  antibodies claimed in the instant application, i.e., having identical structures/sequences, binding kinetics and neutralization properties and wherein the induction dose ranges from about 20 to about 200 mg, from about 80 to about 160 mg and the treatment dose is 40-60% of the induction dose and the treatment dose ranges from about 20 to about 120 mg, from about 40 to about 80 mg and wherein the human anti-human TNF $\alpha$  antibody or antigen-binding fragment thereof is administered subcutaneously and the treatment dose is administered 2 weeks following the induction dose. Claims 1-5, 7, 9-18 and 21 of copending Application No. 11/104,117 do not teach the administration of at least one additional therapeutic agent selected from sirolimus, paclitaxol, everolimus, racolimus, ABT-578 and acetaminophen and wherein the administration is for the treatment of restenosis.

These deficiencies are made up for in the teachings of Clausell et al and Salfeld et al [a] and Poon et al.

Clausell et al have been described supra.

Salfeld et al [a] have been described supra.

Poon et al have been described supra.

The claims in the instant application are obvious variants of claims 1-5, 7, 9-18 and 21 of copending Application No. 11/104,117 because it would have been *prima facie* obvious to one of ordinary skill in the art at the time the claimed invention was made to treat restenosis in a human subject using the human anti-human TNF $\alpha$  antibodies in the multi-variable dose method according to claims 1-5, 7, 9-18 and 21 of copending Application No. 11/104,117, optionally in combination with at least one additional therapeutic agent, including sirolimus.

One of ordinary skill in the art would have been motivated to and had a reasonable expectation of success at the time the invention was made to treat restenosis in a human subject using the human anti-human TNF $\alpha$  antibodies in the multi-variable dose method according to claims 1-5, 7, 9-18 and 21 of copending Application No. 11/104,117, optionally in combination with at least one additional therapeutic agent, including sirolimus in view of Clausell et al and Salfeld et al [a] and Poon et al because Clausell et al teach that restenosis is associated with increased expression of TNF $\alpha$  and fibronectin and neutralization of TNF $\alpha$  activity after cardiac transplantation reduced the severity and number of coronary artery lesions and Salfeld et al [a] teach neutralizing, high affinity human anti-human TNF $\alpha$  antibody and antigen-binding fragments thereof for

treating TNF $\alpha$ -related disorders, including coronary disorders in a human subject comprising administering a therapeutically effective amount of a human anti-human TNF $\alpha$  antibody or antigen-binding fragment thereof identical to the claimed human anti-human TNF $\alpha$  antibodies, i.e., identical structures/sequences, binding kinetics and neutralization properties (discussed supra) and administered with one or more additional therapeutic agents and Poon et al teach sirolimus administration for overcoming restenosis. Therefore, one of ordinary skill in the art at the time the invention was made would have been motivated to use the human anti-human TNF $\alpha$  antibodies and antigen-binding fragments thereof of Salfeld et al [a] for improving restenotic lesions in human patients since TNF $\alpha$  neutralization after cardiac transplantation reduced the severity and number of coronary artery lesions and the human anti-human TNF $\alpha$  antibodies and antigen-binding fragments thereof of Salfeld et al [a] are entirely human anti-human TNF $\alpha$  antibodies and should not elicit an immunogenic response according to Salfeld et al [a] (e.g., pg. 2, lines 8-17). Thus, it would have been *prima facie* obvious to one of ordinary skill in the art at the time the claimed invention was made to treat restenosis in a human subject comprising administering the human anti-human TNF $\alpha$  antibodies of Salfeld et al [a], optionally in combination with at least one additional therapeutic agent, including sirolimus in view of claims 1-5, 7, 9-18 and 21 of copending Application No. 11/104,117 and Clausell et al and Salfeld et al [a] and Poon et al.

Claims 1-5, 7-13, 15-19 and 21-23 are directed to an invention not patentably distinct from claims 1-5, 7, 9-18 and 21 of commonly assigned copending Application No. 11/104,117. Specifically, see above.

The U.S. Patent and Trademark Office normally will not institute an interference between applications or a patent and an application of common ownership (see MPEP Chapter 2300). Commonly assigned copending Application No. 11/104,117, discussed above, would form the basis for a rejection of the noted claims under 35 U.S.C. 103(a) if the commonly assigned case qualifies as prior art under 35 U.S.C. 102(e), (f) or (g) and the conflicting inventions were not commonly owned at the time the invention in this application was made. In order for the examiner to resolve this issue, the assignee can, under 35 U.S.C. 103(c) and 37 CFR 1.78(c), either show that the conflicting inventions were commonly owned at the time the invention in this application was made, or name the prior inventor of the conflicting subject matter.

A showing that the inventions were commonly owned at the time the invention in this application was made will preclude a rejection under 35 U.S.C. 103(a) based upon the commonly assigned case as a reference under 35 U.S.C. 102(f) or (g), or 35 U.S.C. 102(e) for applications pending on or after December 10, 2004.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

20. Claims 1-5, 7-13, 15-19 and 21-23 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-2 and 4-14 of copending Application No. 10/622,932 in view of Poon et al (Lancet, 359(9306):619-622, February 2002). Although the conflicting claims are not identical, they are not patentably distinct from each other.

The instant claims and their interpretation have been described *supra*.

Claims 1-2 and 4-14 of copending Application No. 10/622,932 are drawn to a method of treating a coronary disorder including restenosis in a subject comprising administering a human anti-human TNF $\alpha$  antibodies or an antigen-binding fragment thereof that are identical to the neutralizing, high affinity human anti-human TNF $\alpha$  antibodies and antigen-binding fragments thereof of the present claims, i.e., identical structures/sequences, binding kinetics and neutralization properties and optionally administered with at least one additional therapeutic agent. Claims 1-2 and 4-14 of copending Application No. 10/622,932 not teach the administration of the human anti-human TNF $\alpha$  antibody or antigen-binding fragment thereof in combination with at least one additional therapeutic agent selected from sirolimus, paclitaxol, everolimus, racolimus, ABT-578 and acetaminophen. This deficiency is made up for in the teachings of Poon et al.

Poon et al have been described *supra*.

The claims in the instant application are obvious variants of claims 1-2 and 4-14 of copending Application No. 10/622,932 because it would have been *prima facie* obvious to one of ordinary skill in the art at the time the claimed invention was made to treat restenosis in a human patient comprising administering the

human anti-human TNF $\alpha$  antibodies or an antigen-binding fragment thereof according to claims 1-2 and 4-14 of copending Application No. 10/622,932, optionally with at least one additional therapeutic agent, including sirolimus.

One of ordinary skill in the art would have been motivated to and had a reasonable expectation of success at the time the invention was to treat restenosis in a human patient comprising administering the human anti-human TNF $\alpha$  antibodies or an antigen-binding fragment thereof according to claims 1-2 and 4-14 of copending Application No. 10/622,932, optionally with at least one additional therapeutic agent, including sirolimus in view claims 1-2 and 4-14 of copending Application No. 10/622,932 and Poon et al because claims 1-2 and 4-14 of copending Application No. 10/622,932 teach a method of treating restenosis in a subject comprising administering a human anti-human TNF $\alpha$  antibodies or an antigen-binding fragment thereof that are identical to the neutralizing, high affinity human anti-human TNF $\alpha$  antibodies and antigen-binding fragments thereof of the present claims, i.e., identical structures/sequences, binding kinetics and neutralization properties and optionally administered with at least one additional therapeutic agent and Poon et al teach administration of sirolimus for overcoming restenosis. Thus, it would have been *prima facie* obvious to one of ordinary skill in the art at the time the claimed invention was made to treat restenosis in a human patient comprising administering the human anti-human TNF $\alpha$  antibodies or an antigen-binding fragment thereof according to claims 1-2 and 4-14 of copending Application No. 10/622,932, optionally with at least one additional therapeutic agent, including

sirolimus in view claims 1-2 and 4-14 of copending Application No. 10/622,932

and Poon et al.


This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

### ***Conclusion***

21. No claim is allowed.
22. Any inquiry concerning this communication or earlier communications from the examiner should be directed to David J. Blanchard whose telephone number is (571) 272-0827. The examiner can normally be reached at Monday through Friday from 8:00 AM to 6:00 PM, with alternate Fridays off. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms, can be reached at (571) 272-0832. The official fax number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Respectfully,  
David J. Blanchard  
571-272-0827

A handwritten signature in black ink, appearing to read "David J. Blanchard".